Welcome to our dedicated page for Senseonics Holdings news (Ticker: $SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senseonics Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senseonics Holdings's position in the market.
Senseonics Holdings, Inc. (NYSE American: SENS) will be participating in two upcoming conferences: the RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York, NY. Management will engage in one-on-one meetings at both events, with the RBC conference scheduled for May 15, 2024, and the H.C. Wainwright conference on May 20, 2024. A live and recorded webcast of the presentation will be available on the 'Investor Relations' section of the company's website.
Senseonics Holdings, Inc. (NYSE American: SENS) is set to release its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in the development of long-term, implantable continuous glucose monitoring systems for individuals with diabetes. A conference call to discuss the performance is scheduled for 4:30 p.m. (Eastern Time) on the same day.
The Eversense® CGM System by Senseonics Holdings, Inc. has received an integrated CGM (iCGM) designation by the US FDA, allowing integration with insulin pumps for an automated insulin delivery system. Eversense is the first fully implantable device in its category with iCGM status, offering new interoperable CGM options. The partnership with Ascensia Diabetes Care aims to provide diabetes patients with advanced technology meeting high standards for accuracy, alert detection, and wear time.
